Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies Academic Article uri icon

Overview

MeSH Major

  • Aminopterin
  • Lymphoma, T-Cell

abstract

  • Pralatrexate has significant single-agent activity in patients with relapsed/refractory T-cell lymphoma.

publication date

  • September 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3651599

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.8470

PubMed ID

  • 19652067

Additional Document Info

start page

  • 4357

end page

  • 64

volume

  • 27

number

  • 26